Eplerenone Reduces Atrial Fibrillation Burden Without Preventing Atrial Electrical Remodeling
- PMID: 29216985
- PMCID: PMC5726581
- DOI: 10.1016/j.jacc.2017.10.014
Eplerenone Reduces Atrial Fibrillation Burden Without Preventing Atrial Electrical Remodeling
Abstract
Background: The aldosterone inhibitor eplerenone (EPL) has been shown to reduce the incidence of atrial fibrillation (AF) in patients with systolic heart failure, but the mechanism is unknown.
Objectives: This study hypothesized that by reducing atrial dilation and fibrosis in the absence of heart failure, EPL also reduces AF burden and prevents AF perpetuation.
Methods: The authors conducted a randomized controlled study in 34 sheep that were atrially tachypaced (13 ± 1 week). They compared daily oral EPL (n = 19) versus sugar pill (SP) treatment (n = 15) from the start of tachypacing. The endpoint was a continuous 7-day stretch of persistent AF (n = 29) or completion of 23 weeks tachypacing (n = 5).
Results: EPL significantly reduced the rate of left atrial dilation increase during AF progression. Atria from EPL-treated sheep had less smooth muscle actin protein, collagen-III expression, interstitial atrial fibrosis, and cell hypertrophy than SP-treated sheep atria did. However, EPL did not modify the AF-induced increase in the rate of dominant frequency and ion channel densities seen under SP treatment, but rather prolonged the time to persistent AF in 26% of animals. It also reduced the degree of fibrillatory conduction, AF inducibility, and AF burden.
Conclusions: In the sheep model, EPL mitigates fibrosis and atrial dilation, modifies AF inducibility and AF complexity, and prolongs the transition to persistent AF in 26% of animals, but it does not prevent AF-induced electrical remodeling or AF persistence. The results highlight structural remodeling as a central upstream target to reduce AF burden, and the need to prevent electrical remodeling to avert AF perpetuation.
Keywords: aldosterone; atrial dilation; atrial fibrillation progression; fibrosis; upstream therapy.
Copyright © 2017 American College of Cardiology Foundation. All rights reserved.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5726581/bin/nihms912495f1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5726581/bin/nihms912495f2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5726581/bin/nihms912495f3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5726581/bin/nihms912495f4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5726581/bin/nihms912495f5.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5726581/bin/nihms912495f6.gif)
![Central Illustration](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5726581/bin/nihms912495f7.gif)
Comment in
-
Upstream Targets to Treat Atrial Fibrillation.J Am Coll Cardiol. 2017 Dec 12;70(23):2906-2908. doi: 10.1016/j.jacc.2017.10.043. J Am Coll Cardiol. 2017. PMID: 29216986 No abstract available.
Similar articles
-
Remodeling of myocardial energy and metabolic homeostasis in a sheep model of persistent atrial fibrillation.Biochem Biophys Res Commun. 2019 Sep 10;517(1):8-14. doi: 10.1016/j.bbrc.2019.05.112. Epub 2019 Jul 12. Biochem Biophys Res Commun. 2019. PMID: 31307785
-
Novel Upstream Approaches to Prevent Atrial Fibrillation Perpetuation.Heart Fail Clin. 2016 Apr;12(2):309-22. doi: 10.1016/j.hfc.2015.08.024. Heart Fail Clin. 2016. PMID: 26968673 Review.
-
Effectiveness of aldosterone antagonists for preventing atrial fibrillation after cardiac surgery in patients with systolic heart failure: a retrospective study.Clin Res Cardiol. 2015 Jan;104(1):31-7. doi: 10.1007/s00392-014-0754-7. Epub 2014 Aug 19. Clin Res Cardiol. 2015. PMID: 25134923
-
Antiarrhythmic potential of aldosterone antagonists in atrial fibrillation.Cardiol J. 2012;19(3):223-9. doi: 10.5603/cj.2012.0043. Cardiol J. 2012. PMID: 22641540 Review.
-
Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats.Hypertens Res. 2011 May;34(5):584-91. doi: 10.1038/hr.2010.277. Epub 2011 Jan 20. Hypertens Res. 2011. PMID: 21248754
Cited by
-
Therapeutic advances in atrial fibrillation based on animal models.J Zhejiang Univ Sci B. 2024 Feb 15;25(2):135-152. doi: 10.1631/jzus.B2300285. J Zhejiang Univ Sci B. 2024. PMID: 38303497 Free PMC article. Review.
-
Incidence and progression of atrial fibrillation in patients with and without heart failure using mineralocorticoid receptor antagonists: a meta-analysis.Clin Res Cardiol. 2024 Jun;113(6):884-897. doi: 10.1007/s00392-023-02349-3. Epub 2024 Jan 3. Clin Res Cardiol. 2024. PMID: 38170251
-
Low plasma renin activity is associated with "Apparently" idiopathic atrial fibrillation.Int J Cardiol Heart Vasc. 2023 Oct 24;49:101286. doi: 10.1016/j.ijcha.2023.101286. eCollection 2023 Dec. Int J Cardiol Heart Vasc. 2023. PMID: 37920699 Free PMC article.
-
Research progress of non-coding RNA in atrial fibrillation.Front Cardiovasc Med. 2023 Jul 14;10:1210762. doi: 10.3389/fcvm.2023.1210762. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37522088 Free PMC article. Review.
-
Cardiovascular Disease in Obstructive Sleep Apnea: Putative Contributions of Mineralocorticoid Receptors.Int J Mol Sci. 2023 Jan 23;24(3):2245. doi: 10.3390/ijms24032245. Int J Mol Sci. 2023. PMID: 36768567 Free PMC article. Review.
References
-
- Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113:359–64. - PubMed
-
- Bunch TJ, Weiss JP, Crandall BG, et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer’s dementia. Heart Rhythm. 2010;7:433–7. - PubMed
-
- Lip GY, Tse HF, Lane DA. Atrial fibrillation. Lancet. 2012;379:648–61. - PubMed
-
- Ganesan AN, Chew DP, Hartshorne T, et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. European heart journal. 2016;37:1591–602. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical